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Cell-cell adhesion mediated by desmosomes is crucial for maintaining proper epidermal structure and function, as evidenced by
several severe and potentially fatal skin disorders involving impairment of desmosomal proteins. Pemphigus foliaceus (PF) and
staphylococcal scalded skin syndrome (SSSS) are subcorneal blistering diseases resulting from loss of function of the desmosomal
cadherin, desmoglein 1 (Dsg1). To further study the pathomechanism of these diseases and to assess the adhesive properties of
Dsg2, we employed a recently established transgenic (Tg) mouse model expressing Dsg2 in the superficial epidermis. Neonatal Tg
and wild type (WT) mice were injected with purified ETA or PF Ig. We showed that ectopic expression of Dsg2 reduced the extent
of blister formation in response to both ETA and PF Ig. In response to PF Ig, we observed either a dramatic loss or a reorganization
of Dsg1-α, Dsg1-β, and, to a lesser extent, Dsg1-γ, in WT mice. The Inv-Dsg2 Tg mice showed enhanced retention of Dsg1 at the
cell-cell border. Collectively, our data support the role for Dsg2 in cell adhesion and suggest that ectopic superficial expression of
Dsg2 can increase membrane preservation of Dsg1 and limit epidermal blister formation mediated by PF antibodies and exfoliative
toxins.
1. Introduction
Desmogleins and desmocollins are the transmembrane
adhesive components of intercellular junctions known as
desmosomes. Four distinct desmogleins (Dsg 1-4) have
been reported with unique expression profiles dependent
on the tissue type and diﬀerentiation state [1, 2]. Unlike
Dsg1 and Dsg3, whose expression is restricted to complex
stratified epithelia, Dsg2 and Dsg4 are expressed in a wide
range of other cell types. In stratified epithelia, such as
the human epidermis, Dsg2 is expressed at low levels and
is restricted to the proliferative basal cell layer while Dsg3
expression extends from the basal into the spinous cell
layers. Conversely, Dsg1 and Dsg4 expression is driven by
cell diﬀerentiation. Dsg1 is expressed from the immediate
suprabasal layer up, with marked higher abundance in
the diﬀerentiated granular cell layers. Dsg4 expression is
restricted to the highly diﬀerentiated upper cell layers.
It is well established that desmosomal cadherins play
a significant role in cell adhesion and tissue integrity, as
they have been identified as the target proteins in several
autoimmune, infectious, and inherited skin/hair fragility
diseases [3]. Pemphigus is a devastating and debilitating
autoimmune skin disease [4]. This disorder is generally
characterized by the production of pathogenic antibodies
targeting diﬀerent components of cell-cell adhesion, in
particular, Dsg1 and Dsg3. The autoantibodies commonly
cause cell-cell disadhesion (acantholysis), as well as blis-
ters of the skin and mucous membranes. In pemphigus
foliaceus (PF), patients develop pathogenic autoantibodies
that target Dsg1 and promote cell-cell disadhesion in the
superficial epidermis, where Dsg1 is highly expressed, but
which lacks Dsg3 and Dsg2. Passive transfers of puri-
fied PF Ig into newborn mice produce blisters similar
to those observed in PF patients [5, 6]. Interestingly,
in the toxin-mediated disease bullous impetigo (and its
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generalized form staphylococcal scalded skin syndrome
(SSSS)), the bacterium S. aureus produces exfoliative tox-
ins (glutamic-specific serine proteases) that cleave Dsg1
between extracellular domains 3 and 4 [7]. Reminiscent
of PF, SSSS patients develop superficial skin blisters [8].
Furthermore, newborn mice treated with exfoliative toxins
develop skin blisters similar to those observed with the
passive transfer of PF Ig. Both pathogenic pemphigus
autoantibodies and exfoliative toxins target specific confor-
mational epitopes found within the N-terminal extracellular
domains of desmogleins [9]. These domains are believed
to play an important role in cadherin-cadherin interac-
tion, thereby alluding to the importance of desmogleins
in controlling intercellular adhesion and in maintaining
the structural stability and integrity of the epidermis [10–
13].
To assess the ability of Dsg2 to enhance cell adhesion and
to test the hypothesis that Dsg2 expression in the suprabasal
epidermis can limit PF/ETA blister formation by increasing
keratinocyte adhesion, we employed a transgenic mouse
model expressing Dsg2 in the superficial epidermis under
the involucrin promoter (Inv-Dsg2 Tg) [14]. We selected
Dsg2 since it is not a pemphigus antigen [15] and does not
appear to have the consensus sequence required for cleavage
by exfoliative toxins. We subjected the Tg mice and their WT
littermates to ETA and PF Ig treatments and assessed the
extent of skin blister formation. These experiments allowed
us to compare the relative intensity of the ETA- and PF-
induced blister formation in the presence or absence of
Dsg2 in the superficial epidermis. The results obtained here
provide some insights into the pathomechanisms of diseases
targeting Dsg1.
2. Results
2.1. Expression of Dsg2 in the Superficial Epidermis of Inv-Dsg2
Tg Mice. As previously described in detail, we generated Tg
mice expressing Dsg2 in the superficial epidermis, under
the control of the involucrin promoter [14]. Newborn Tg
mice appeared normal, with no gross abnormalities of
the skin or hair. Examination of the skin by histology
revealed minor epidermal hyperplasia in newborn Tg mice
compared to WT littermates (Figure 1(a)). We assessed the
expression of the Dsg2-Flag transgene in skin from newborn
Tg mice by immunostaining; antibodies against Flag and
Dsg2 (MP6) (Figure 1(b)) showed expression of Dsg2-Flag
in the superficial cell layers. In keeping with the literature, we
observed some negligible expression of endogenous Dsg2 in
the basal cell layer.
To confirm the immunoblotting results, we extracted
total skin protein from WT and Tg skin in RIPA buﬀer
and resolved it with SDS-PAGE. Immunoblotting with the
MP6 and Flag antibodies detected bands of approximately
160 kDa in Tg skin lysates (Figure 1(c)). MP6, but not Flag,
antibody picked up a weak signal for a similar sized band in
the WT skin, which is indicative of low levels of endogenous
Dsg2 in the newborn mouse skin. In summary, we generated
transgenic mice expressing Dsg2 in the superficial epidermis
of newborn mice.
2.2. Dsg2 Protects Skin from ETA-Mediated Blister Formation.
It is well established that ETA cleaves Dsg1 and causes
epidermal blisters in the upper layers of the epidermis, where
Dsg1 is highly expressed [16]. Mice treated with purified ETA
develop blisters similar to those seen in patients infected with
S. aureus. To determine whether Dsg2 could compensate
for the loss of Dsg1, we treated neonatal WT and Tg mice
with purified ETA. In response to subcutaneous injection of
ETA, we observed dramatic gross blisters in WT, but not Tg,
mice (Figure 2(a)). However, the results from the histologic
analysis were less definitive, since some Tg mice developed
extensive blisters while others showed a resistance to blister
formation (Figure 2(b), top panels).
Upon further analysis, we observed that the site of
blister formation in WT mice after ETA treatment was
superficial and occurred in the middle of the granular cell
layer (Figure 2(b), lower left panel), where Dsg1 is highly
expressed. However, in the Inv-Dsg2 Tg skin treated with
ETA, the site of epidermal splitting was often just beneath
the granular cell layer (Figure 2(b), lower right panel). These
results suggest that coexpression of Dsg2 with Dsg1 in the
superficial epidermis may protect from the loss of Dsg1 by
ETA although we cannot rule out the possibility that ectopic
expression of Dsg2 may also impair the ETA-digestion of
Dsg1 molecules. However, the latter scenario is unlikely, as
ETA is enzymatically eﬃcient, and we did not observe any
significant increase in uncleaved Dsg1 in ETA-treated Tg
mice (see below).
The extent of the histologic blistering was graded on a
scale from 0, for no blisters, to +4, for extensive blisters.
We observed that overexpression of Dsg2 provided enhanced
protection against blister formation in response to ETA
(Figure 2(c)). To confirm that ETA cleaves mouse Dsg1 when
injected into newborn WT and Tg mice, skin biopsies were
taken after ETA treatment and the total cellular proteins
were extracted in Laemmli buﬀer. Western blotting showed
that ETA cleaves Dsg1, resulting in a smaller fragment
approximately 113 kDa in both WT and Inv-Dsg2 Tg mouse
skin (arrow, Figure 2(d)) [8, 16]. We previously showed
that antibody 27B2 recognizes an epitope present in the
cytoplasmic domain of all mouse Dsg1 (α, β, and γ) isoforms
[17]. In that report, we also demonstrated that ETA cleaves
only Dsg1-α and -β. Thus, the remaining full-length Dsg1
fragment left after ETA-treatment observed here is most
likely Dsg1-γ, but may also show ineﬃcient Dsg1-α or -
β cleavage. Interestingly, we observed a slight increase in
Dsg1 in the ETA treated Tg skin (Figure 2(d)). This increase
in Dsg1 was reflected in a more intense 113 kDa band in
response to ETA cleavage. Finally, we showed here that ETA
did not cleave Dsg2.
To assess whether ectopic expression of Dsg2 in the
Tg skin had an eﬀect on Dsg1 in response to ETA, we
performed immunofluorescence staining for Dsg1. We deter-
mined the expression pattern of Dsg1-α, -β, and -γ using
antibodies specific against each Dsg1 isoform (Figure 3).
These antibodies were generated against either synthetic
peptides or recombinant proteins localized within the extra-
cellular domain of Dsg1 and would thus detect the full-
length, membrane-spanning product after ETA digestion
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Figure 1: Suprabasal expression of Dsg2-Flag in newborn Inv-Dsg2 transgenic mice. (a) Histology showing slight epidermal hyperplasia
in a newborn Inv-Dsg2 Tg overexpressing Dsg2 in the superficial epidermis under the involucrin promoter, but not in WT mice. (b)
Immunostaining of newborn Tg skin with Flag (green) and Dsg2-specific MP6 (red) antibodies showing expression of Dsg2-Flag in the
diﬀerentiated cell layers of the transgenic epidermis. (c) Immunoblot of WT and Tg skin with MP6 and Flag antibodies, showing Dsg2-Flag
in the Tg but not WT skin. Actin was used for equal loading.
[17]. Despite the extensive cleavage of Dsg1 by ETA, as
shown by Western blotting above, we did not observe a
dramatic change in the Dsg1 pattern in either WT or Tg
skin. Dsg1 remained intact at the cell-cell border. To further
confirm these results, we immunostained ETA-treated WT
and Tg skin with antibody 27B2, which was raised against
the intracellular domain of human Dsg1 and recognizes
all three mouse Dsg1s. Staining with 27B2 showed cell-cell
border staining of Dsg1s even at the blister sites (Figure 3).
Collectively, our results demonstrate that ectopic expression
of Dsg2 could partially compensate for the loss of Dsg1-
mediated adhesion in response to ETA digestion.
2.3. Dsg2 Protects against PF Ig-Mediated Blister Formation.
Next, we wanted to assess whether ectopic expression of
Dsg2 could protect against skin blister formation induced
by PF pathogenic antibodies. We purified Ig from the sera
of PF patients with the active disease and performed passive
transfer of the PF Ig into newborn WT and Tg mice. We,
and others, have shown that mice injected with normal
human Ig do not develop skin blister formation [6]. In
accordance with the literature, we observed extensive gross
blisters in WT mice 18 hours after injection with PF Ig
[6]. However, the Inv-Dsg2 Tg mice injected with PF Ig
developed significantly less extensive blisters (Figure 4(a)).
The severity of skin blistering was similar between gross
observation and histological analysis (Figure 4(b)). Again
similar to the blistering observed with ETA in Figure 2,
we observed a slight downward shift in the site of blister
formation in Tg, as compared to WT, skin (Figure 4(b), lower
panels). The extent of histological blistering was then graded,
and the results showed that Tg mice were less susceptible
to blister formation in response to PF Ig (Figure 4(c)).
Thus, ectopic expression of Dsg2 in the superficial epidermis
rendered the Tg mice more resistant to PF Ig-induced skin
blisters.
To test the eﬀects of PF Ig on epidermal Dsg1, skin
biopsies were collected after PF Ig treatment, and the total
cellular proteins were extracted in Laemmli buﬀer. Western
blotting showed that (1) up-regulation of Dsg2 did not
alter the expression level of Dsg1 in newborn mouse skin,
and (2) incubation with PF Ig reduced the level of Dsg1
(Figure 4(d)). Thus, our results demonstrate that, at the
Western blot level, PF Ig depletes Dsg1 and that superficial
expression of Dsg2 in Tg mice did not appear to modulate
the level of Dsg1 in response to PF Ig.
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Figure 2: Superficial expression of Dsg2 oﬀers protection from ETA-induced blister formation. (a) Newborn WT and Inv-Dsg2 Tg mice were
injected subcutaneously with 0.5 μg ETA in PBS. Visible blisters were observed in WT but not Tg mice, 6–8 hours after ETA treatment. (b)
Mice were sacrificed, and their skin was processed for histological analysis, revealing slightly more extensive blisters in the WT mice (n = 14),
as compared to Tg mice (n = 23), in response to ETA. Top panels show 3X magnification, and lower panels show 40X magnification of the
site of blister formation. (c) The extent of blistering was graded based on the following semiquantitative scale: 0: no blisters, 1+: minor
blisters at the edge; 2+: localized blisters <50%; 3+: extensive blisters >50%; and 4+: very extensive blisters >75%. Each dot represents one
mouse. The average blister scores were 2.6 ± 1.2 for WT and 1.7 ± 1.3 for Tg. These values were statistically significant, P ≤ .038260921
(2-tailed unequal variance) or ≤ .01913046 (1-tailed unequal variance). (d) The back skin biopsies were homogenized in Laemmli buﬀer,
proteins were resolved with SDS-PAGE and immunoblotted for Dsg1 (27B2), Dsg2-Flag (Flag), and Actin (for equal loading). Western
blotting demonstrates that ETA cleaved Dsg1 (arrowhead), but not Dsg2. Note. antibody 27B2 was raised against the cytoplasmic epitope of
human Dsg1, and recognizes mouse Dsg1-a, -β, and -γ. Thus, the full-length signal is most likely ETA-resistant Dsg1-γ.
Dermatology Research and Practice 5
WT Tg
Dsg1-α
Dsg1-β
Dsg1-γ
Dsg1s
Figure 3: Dsg1 is maintained at the cell-cell border in ETA-treated epidermis. Formalin-fixed paraﬃn-embedded skin sections from
newborn WT and Tg mice treated with ETA, as described in Figure 2, were immunostained with antibodies AP61, AP498, Ab15, and
27B2. Antibodies AP61, AP498, and Ab15 were raised against the extracellular domain of Dsg1-α, Dsg1-β, and Dsg1-γ, respectively [17].
Immunofluorescence shows undisturbed cell-cell border staining of all Dsg1 isoforms in both WT and Tg skins treated with ETA. DAPI
(blue) was used as a nuclear stain. Similar results were observed in skin treated with ETA for 18 hours. Arrows demarcate site of blister
cleavage.
Next, we wanted to evaluate whether or not superficial
expression of Dsg2 had an eﬀect on Dsg1 fate and localization
in response to PF Ig. We first confirmed, by direct immunos-
taining, the presence of human antibodies in the skin of mice
treated with PF Ig (Figure 5(a), left panels). The human Ig
was detected in the epidermis of both WT and Tg skin. In
WT skin, staining for human antibodies was diﬀuse and was
disrupted by some cytoplasmic staining. Interestingly, in the
Tg epidermis, the staining for human antibodies was clearly
at the cell-cell borders, suggesting, perhaps, the presence
of more intact desmosomes (Figure 5(a), lower left panel).
We also immunostained the same tissues for Dsg2-Flag to
demonstrate that Tg, but not WT, mice expressed the Dsg2-
Flag transgene (Figure 5(a), middle panels). Double labeling
(Figure 5(a), right panels) showed colocalization (yellow) of
Dsg2 (green) and human Ig (red) at the cell-cell border in the
superficial epidermis (lower right panel).
Next, we assessed the expression and localization of Dsg1
(α, β, and γ) by indirect immunofluorescence (Figure 5(b)).
In WT animals, PF Ig treatment induced extensive redistri-
bution of Dsg1-α and Dsg1-β from a uniform cell-cell border
pattern to a disrupted granular pattern, which is indicative
of potential dissolution of the desmosomes (Figure 5(b), left
panels). The dissolution occurred throughout the epidermis
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Figure 4: Dsg2 oﬀers protection against PF Ig-induced acantholysis. (a) Newborn WT and Inv-Dsg2 Tg mice were injected subcutaneously
with 10 mg of purified PF Ig for 18 hours. Gross blisters were more pronounced in WT mice, as compared to Tg mice. (b) Mice were
sacrificed, and their skin was processed for histology, revealing more dramatic blisters in the WT (n = 6) than in Tg mice (n = 10). Top
panels show 3X magnification, and lower panels show 40X magnification of the site of blister formation (arrows). (c) The extent of blistering
was graded as described in Figure 2. Each dot represents one animal. The average blister scores were 4.0 ± 0.0 for WT mice and 2.1 ± 0.7 for
Tg mice. These values were statistically significant, P ≤ .000022 (2-tailed unequal variance) or ≤ .000012 (1-tailed unequal variance). (d)
Back skin biopsies of WT and Tg mice treated with PF Ig were homogenized in Laemmli buﬀer, the proteins were resolved with SDS-PAGE
and immunoblotted for Dsg1 (27B2), Dsg2, and Actin. Western blotting demonstrates that superficial Dsg2 slightly enhances retention of
Dsg1 in response to PF Ig.
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Figure 5: Superficial expression of Dsg2 reduces disruption of Dsg1 in response to PF Ig. Newborn WT and Dsg2 Tg mice were injected
subcutaneously with PF Ig, and, 18 hours later, back skin samples were frozen in OCT or were fixed in formalin and embedded in paraﬃn
for immunostaining. (a) Direct immunostaining for human Ig (hIg, left panels), showing localization of human antibodies to the epidermis
after PF Ig passive transfer. The same tissue was immunostained with Flag antibodies, demonstrating the presence of Dsg2-Flag in the Tg, but
not WT, skin (middle panels). Double labeling for the human Ig (red) and the Flag tag (green) is shown (right panels). Staining of human
Ig was considerably more intact at the cell-cell border in the Tg skin, particularly in the superficial epidermis, where Dsg2 was expressed.
Thus, superficial Dsg2 retains PF Ig at the cell-cell borders. (b) Lesional and nonlesional back skin sections were then immunostained with
antibodies AP61, AP498, and Ab15, which were raised against the extracellular domain of Dsg1-α, Dsg1-β, and Dsg1-γ, respectively. DAPI
(blue) was used as a nuclear stain. Arrows demarcate site of blister cleavage (lesional skin). In WT mice, treatment with PF Ig dramatically
disrupted cell-cell border staining of Dsg1-α and Dsg1-β but not Dsg1-γ (left panels). Superficial expression of Dsg2 reduced the extent of
Dsg1 perturbation (internalization and degradation). There was no significantly observable diﬀerence between lesional and non-lesional
epidermis.
but was more extensive in the less diﬀerentiated cell layers.
Intriguingly, PF Ig had a minor eﬀect on Dsg1-γ, showing
a slight reduction in the deep epidermis as compared to
untreated control skin. In Tg mice treated with PF Ig, the
presence of Dsg2 in the superficial epidermis helped retain
Dsg1 at the cell-cell border (Figure 5(b), middle and right
panels). The level of Dsg1 dissolution was not dramatically
diﬀerent between unaﬀected and lesional skin. In conclusion,
superficial expression of Dsg2 appears to maintain the
organization of Dsg1 in response to PF Ig treatment.
8 Dermatology Research and Practice
3. Discussion
In this paper, we showed that superficial expression of Dsg2
in Tg mice oﬀers protection against skin blister formation
in response to the bacterial toxin ETA and pathogenic PF
antibodies. These results suggest that Dsg2 can enhance
mechanical adhesion, likely contributing to this protective
eﬀect. In the case of ETA, this enhancement could counter
the loss of adhesive function due to the removal of sequences
in the ectodomain of Dsg1 known to be important for
desmoglein-dependent adhesion [12, 13]. In the case of
PF Ig, increased adhesion may compensate for possible
steric hindrance of desmoglein trans-interaction induced by
antibody-antigen binding [6, 18, 19].
Despite considerable progress in pemphigus research,
there is still a controversy over the mechanism of pemphigus
Ig-induced acantholysis—is it a disease of steric hindrance,
cell signaling, or both? Steric hindrance of desmoglein
trans-interaction induced by antibody-antigen binding was
initially proposed based on evidence that one desmoglein
could compensate for the loss of another [6, 18, 19]. The
most compelling data supporting this hypothesis comes
from a study showing that ectopic expression Dsg3 in the
superficial epidermis of Tg mice [19] protects from blister
formation induced by PF antibodies [20]. Furthermore,
toxins such as ETA can induce PF-like skin blisters by
proteolysis of Dsg1 in the absence of antibody binding [16].
In this paper, we demonstrate that ectopic expression of Dsg2
in the superficial epidermis could limit both PF Ig- and
ETA-induced skin blister formation, suggesting that steric
hindrance plays a role in the mechanism of pemphigus.
However, desmoglein compensation in response to
pathogenic antibodies may work through mechanisms other
than steric hindrance [3, 21, 22]. Indeed, in the case of
PF, anti-Dsg1 antibodies can induce blister formation by
triggering intracellular signaling pathways, without disrupt-
ing Dsg1-Dsg1 interactions [23]. Intracellular signaling may
then promote alterations in cortical actin remodeling and
may induce other changes that lead to the depletion of
desmogleins from the desmosome and lead to consequent
blistering. It is possible that Dsg2 counters the impact of PF
Ig on these pathways, resulting in the retention of Dsg1 at the
cell surface and maintenance of desmosome structure and
function.
Also, suprabasal expression of Dsg2 in Tg mice oﬀers
greater protection against PF Ig, as compared to ETA
(Figure 4). The diﬀerence in the response to ETA and PF
Ig in transgenic mice may be due to diﬀerences in the
mechanism by which ETA and PF Ig induce blistering, the
mechanism by which suprabasal Dsg2 limits the blistering,
or both. For instance, whereas PF antibodies disrupt and
reduce cell-cell border staining of Dsg1 (Figure 5), ETA
cleavage does not appear to alter the plasma membrane
localization of Dsg1 despite inducing extensive skin blisters
(Figure 3). It is possible that retention of this truncated
Dsg1 molecule at the cell surface may attenuate Dsg2’s
protective eﬀects. In addition, either alterations in the
subcellular distribution of armadillo proteins or the dif-
ferential impact on other signaling pathways could also
account for the observed diﬀerences in Dsg2’s protective
eﬀect between ETA- or PF-treated Tg mice. It has been
reported that pemphigus antibodies trigger a rapid turnover
and reduction of the nuclear pool of plakoglobin, thereby
abolishing plakoglobin’s role as a transcriptional repressor of
the proto-oncogene c-Myc [24]. We recently demonstrated
that Dsg2 enhances c-Myc expression [14]. In that study,
we demonstrated that Dsg2 plays a role in cell signaling
activation, and many signaling pathways directly involved in
epithelial cell growth and survival are activated in Dsg2 Tg
mice.
In summary, we propose that desmogleins mediate cel-
lular homeostasis through cell-cell adhesion and activation
of signaling pathways; changes in desmosome structure
and integrity by pemphigus antibodies or ETA can disrupt
this balance. Compensating with another desmoglein can
oﬀset this deregulation, thus restoring homeostasis, possibly
through a combination of cell-cell adhesion and the regula-
tion of cell signaling. What remains to be addressed in future
studies is (1) whether ectopic expression of Dsg2 alters the
sensitivity of Dsg1 to degradation by ETA or loss of function
upon antibody binding, and (2) whether the loss of Dsg1
function in pemphigus is caused by altered signaling and/or
steric hindrance.
Currently, there are no FDA-approved prescription drugs
specifically for the treatment of pemphigus. The combi-
nation of corticosteroids and other nonsteroidal immuno-
suppressive or anti-inflammatory drugs oﬀers the most
eﬀective means to lower mortality while reducing long-
term morbidity due to chronic systemic exposure to steroids
[25]. Several ongoing clinical trials targeting cell-signaling
molecules such as p38MAPK and TNF-a appear promising
[26, 27]. As mentioned above, we recently demonstrated
that Dsg2 activates multiple growth and survival pathways,
including PI 3-kinase/AKT, MEKMAPK, STAT3, and NF-
κB. In this paper, we show that Dsg2 can limit epidermal
blister formation mediated by PF antibodies. Thus, finding
a drug/agent that could increase Dsg2 levels in the skin or,
preferably, activate the signaling pathways downstream of
Dsg2 oﬀers a potential therapeutic treatment for this life-
threatening blistering disease.
4. Materials and Methods
4.1. Histology, Immunohistochemical Staining, and Immunob-
lotting. For histology, skin tissues were fixed at room tem-
perature overnight in a 10% formalin solution. Tissues were
then processed for paraﬃn embedding, sectioned (5 μm),
mounted on glass slides, and stained with Hematoxylin and
Eosin.
For immunohistochemistry, mouse skin biopsies were
fixed in either OCT or 10% formalin (Sigma) and were
embedded in paraﬃn. Tissues were sectioned (5 μm) as
previously described in detail [6, 17]. To detect normal
human Ig, the Flag tag, or Dsg1, OCT frozen sections were
fixed in methanol (−20◦C) for 15 minutes, permeabilized
with 1% TX-100 in PBS for 5 minutes, and blocked in
IF blocking buﬀer (5% normal goat serum, 1% BSA,
and 0.02% TX-100 in PBS) for 1 hour at RT. Tissues
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were incubated with primary antibodies (anti-Flag (1 : 1000,
Sigma) and 27B2 (1 : 10)) overnight at 4◦C and secondary
antibodies for 1 hour at room temperature. Antibodies were
incubated in IF blocking buﬀer. For polyclonal antibodies
against mouse Dsg1 isoforms, paraﬃn embedded tissues
were deparaﬃnized in 100% xylene (5 minutes; 3 times),
100% ethanol (5 minutes; 2 times), 95% ethanol (5 min-
utes; 2 times), 75% ethanol (2 minutes), 50% ethanol (2
minutes), and H2O (2 minutes). Antigens were retrieved
in an antigen-retrieving medium (Signet, Dedham, MA) by
the microwave method and digestion with trypsin (Sigma).
Primary and secondary antibodies were suspended in IF
blocking buﬀer. Nuclei were stained with DAPI (Sigma), and
slides were mounted for analysis via fluorescence microscopy.
Polyclonal antibodies against mouse Dsg1 include AP61
(Dsg1-α; 1 : 100), AP498 (Dsg1-β, 1 : 100), and Ab15 (Dsg1-
γ, 1 : 1000). Alexa Fluor-conjugated secondary antibodies
(488 and 594 nm) were from Invitrogen (Eugene, OR)
and were used at 1 : 200. Images were acquired using a
Hamamatsu monochromatic digital camera and Phase 3
Imaging Systems software (Glen Mills, PA, USA; C4742–
95).
In preparation for immunoblotting, mouse back skin was
pulverized in liquid nitrogen in RIPA buﬀer (50 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxy-
cholate, 0.1% SDS, and a protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, IN)). Protein concentration was
determined (Pierce BCA kit, Pierce Biotech, Rockford, IL),
and immunoblotting was performed, as described previously
[17], with 20 μg of protein in each lane resolved with 7%
SDS-PAGE (Bio-Rad Laboratories, Hercules, CA). Signals
were detected with chemiluminescence (ECL; Amersham
Biosciences, Piscataway, NJ). Antibodies used were 27B2
(1 : 100), Flag (1 : 1000), and Actin (1 : 10 000).
4.2. PF Ig Purification. Preparation of serum Ig was done
as previously described [28]. Briefly, human sera (10–20 ml)
were dialyzed overnight at 4◦C against 20 mM KH2P04 (pH
8.0), and 0.02% sodium azide and was purified with a DEAE
Aﬃ-Gel Blue column (Bio-Rad Labs, Hercules, CA). Serum
Ig was concentrated using Centriprep10 (Amicon Millipore,
Billerica, MA) and was dialyzed against PBS at 4◦C. Protein
concentration was determined, and the sera were stored at
−80◦C.
4.3. Passive Transfer of Pemphigus Ig and Injection of ETA
into Neonatal Mice. Newborn mice (∼2 g) were injected
subcutaneously with purified Ig (10 mg in 100 μl) between
the shoulder blades with a 1 cc insulin syringe (Becton
Dickinson) as previously described [6]. For ETA treatment,
newborn control and Tg mice were injected subcutaneously
in the back of the neck with either ETA (0.5 μg in 50 μl
PBS, Toxin Technology, Sarasota, FL) or PBS alone as
previously described [8]. Animals were photographed and
sacrificed, and their back skin was processed in 10% PBS-
buﬀered formalin (Sigma) for histology and in OCT for
immunohistochemistry or was frozen in liquid nitrogen for
DNA and protein extraction.
Abbreviations
ETA: Exfoliative toxin A
Dsg: Desmoglein
PF: Pemphigus foliaceus
PV: Pemphigus vulgaris
Tg: Transgenic
WT: Wild-type.
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